Heart & lung : the journal of critical care · 2026
Impact of CT incidental lung findings and pulmonary function on 3-year mortality after transcatheter aortic valve replacement (TAVR).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mousa Basha Mustafa, Hein Louisa, Mohr Sophia, Al-Kassou Baravan, Weber Marcel, Beiert Thomas, Zimmer Sebastian, Luetkens Julian, Kütting Daniel, Bakhtiary Farhad, Nickenig Georg, Skowasch Dirk, Pizarro Carmen, Shamekhi Jasmin
Аннотация
BACKGROUND: Incidental pulmonary findings, particularly interstitial lung abnormalities (ILA) and emphysema are frequently observed in preprocedural computed tomography (CT) scans of patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). However, their prognostic significance remains unclear.
OBJECTIVES: To evaluate the impact of incidental lung findings on 3-year all-cause mortality and pulmonary function in TAVR patients.
METHODS: In this retrospective study, we analysed 572 patients who underwent transfemoral TAVR at the Heart Center Bonn between January 2018 and December 2021. All patients underwent preprocedural CT and comprehensive pulmonary function testing. Primary endpoint was 3-year all-cause mortality.
RESULTS: Radiological evidence of ILA was present in 20.8%. ILA was significantly associated with increased 3-year mortality (57.6% vs. 36.4%; p < 0.001). In multivariable analysis, ILA remained an independent predictor of mortality (HR 1.59, 95% CI 1.17-2.19, p = 0.004), alongside FVC < 80% predicted. Stratified analysis revealed that the prognostic impact of reduced FVC was confined to patients with ILA (p = 0.015), whereas no significant association was observed in patients without ILA (p = 0.058). ILA patients demonstrated significantly impaired pulmonary function, with lower FVC (65.2 ± 16.6% vs. 72.0 ± 18.0%; p < 0.001), and decreased DLCO (47.4 ± 21.1% vs. 55.9 ± 21.1%; p = 0.019) compared to patients without ILA.
CONCLUSION: Incidental ILA detected on preprocedural CT is a strong and independent predictor of 3-year mortality in TAVR patients. ILA was associated with a restrictive and diffusion-limited pulmonary function pattern, emphasizing the need of integration of pulmonary function tests to facilitate better follow-up and monitoring of interstitial lung disease progression.
OBJECTIVES: To evaluate the impact of incidental lung findings on 3-year all-cause mortality and pulmonary function in TAVR patients.
METHODS: In this retrospective study, we analysed 572 patients who underwent transfemoral TAVR at the Heart Center Bonn between January 2018 and December 2021. All patients underwent preprocedural CT and comprehensive pulmonary function testing. Primary endpoint was 3-year all-cause mortality.
RESULTS: Radiological evidence of ILA was present in 20.8%. ILA was significantly associated with increased 3-year mortality (57.6% vs. 36.4%; p < 0.001). In multivariable analysis, ILA remained an independent predictor of mortality (HR 1.59, 95% CI 1.17-2.19, p = 0.004), alongside FVC < 80% predicted. Stratified analysis revealed that the prognostic impact of reduced FVC was confined to patients with ILA (p = 0.015), whereas no significant association was observed in patients without ILA (p = 0.058). ILA patients demonstrated significantly impaired pulmonary function, with lower FVC (65.2 ± 16.6% vs. 72.0 ± 18.0%; p < 0.001), and decreased DLCO (47.4 ± 21.1% vs. 55.9 ± 21.1%; p = 0.019) compared to patients without ILA.
CONCLUSION: Incidental ILA detected on preprocedural CT is a strong and independent predictor of 3-year mortality in TAVR patients. ILA was associated with a restrictive and diffusion-limited pulmonary function pattern, emphasizing the need of integration of pulmonary function tests to facilitate better follow-up and monitoring of interstitial lung disease progression.